GSK pays $1.2B upfront for Boston's lead liver disease drug

fiercebiotech.com/biotech/gsk-pays-12b-upfront-boston-pharmaceuticals-lead-liver-disease-drug

This story appeared on fiercebiotech.com, 2025-05-14 21:44:20.683000.
The Entire Business World on a Single Page. Free to Use →